dimanche 15 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· April 10, 2026

Shopify Eyes 18% Upside After Sharp 2026 Selloff

View original at finance.yahoo.com
“Fourth quarter revenue reached $3.67 billion, up 30.58% year-over-year, beating the consensus estimate by 2.34%. Free cash flow came in at $715 million with a 19% margin.”
Verbatim excerpt from the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Bulls see potential for stock to reach $183 and higher based on compounding growth across multiple vectors

    60% confidence
  • AI commerce tools including Catalog, Sidekick, and Universal Commerce Protocol could meaningfully lift merchant attach rates over two to three years

    60% confidence
  • Recommendation is BUY with 90% confidence level

    60% confidence
  • Shopify shares have 17.68% upside potential with price target of $132.25 from current price of $112.38

    60% confidence
  • The 38% discount to 52-week high presents opportunity given intact operational momentum and early-stage monetization potential in AI commerce tools and cross-border expansion

    60% confidence

Data points we hold from this source

Shopify Inc. · one month return-13.13 percent
Shopify Inc. · ytd return-30.19 percent
Shopify Inc. · price target132.25 USD
Shopify Inc. · operating income growth35.7 percent
Shopify Inc. · country presence175 countries
Shopify Inc. · free cash flow margin19 percent
Shopify Inc. · b2b gmv growth96 percent
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com